Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00425256

Enrollment

Unknown

Registered

2007-01-22

Start date

2006-02-28

Completion date

2007-05-31

Last updated

2011-02-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sexual Arousal Disorder

Brief summary

This 8 week at home study is designed to explore efficacy endpoints and evaluate the safety of intranasal Bremelanotide in women with Female Sexual Arousal Disorder. Efficacy will be assessed vs. a parallel placebo group.

Interventions

DRUGBremelanotide

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Masking

DOUBLE

Eligibility

Sex/Gender

FEMALE

Age

21 Years to 70 Years

Inclusion criteria

* Post menopausal and in general good health * In a stable relationship with a male partner for at least 6 months * Willing to attempt sexual activity once a week with your partner

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026